Back to Research Hub
Krystal Biotech, Inc.
KRYS
$309.75+7.99 (+2.65%)
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa.
StreetsValue research for Krystal Biotech, Inc. (KRYS)
Members get the full report for Krystal Biotech, Inc.: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.